



HELIX

biopharma

HELIX LOOP

Your inside track on Helix BioPharma – August 2025

We're delighted to bring you the second edition of the **Helix Loop**—your bi-monthly window into the people, progress, and priorities shaping Helix BioPharma.

In this edition, we're building on a summer of momentum. Our pipeline is advancing, our financing base is strengthening, and our team is expanding to carry us into the next stage of growth.

Thank you for staying connected with us as our journey unfolds. Together, we're moving into an exciting new chapter.

Inside this issue:

-  Pipeline progress
-  Financing updates
-  Leadership expansion
-  Traction

Pipeline Highlights

- L-DOS47 Phase IB in NSCLC: In August, we received positive and constructive FDA feedback on our Phase IB/Randomized Phase 2 study design of L-DOS47 with pembrolizumab in NSCLC, and we're now moving forward with full protocol development and clinical supply readiness.
- LEUMUNA™ and GEMCEDA™: Following the closure of the asset acquisitions from the Laevoroc Group in on 16 May 2025, we are preparing for a pre-IND meeting with the FDA to start the clinical development of LEUMUNA in patients relapsing with acute leukemia after stem cell transplantation.
- CEACAM6 ADC: We are concentrating on a nanobody-radioisotope approach for pancreatic cancer and are moving quickly toward nominating a lead candidate.

Financing Updates

- [Second private placement of CAD \\$1.6M closed on 22 August 2025](#)
- Third private placement to be closed following price protection approval from the TSX.
- Institutional investment anticipated in Q4 2025.
- NASDAQ uplisting anticipated in Q1 2026.

Building a World Class Team

A key leadership addition since June 2025:

- **Mr. Rohit Babbar, CPA** — CFO

Helix is further supported by an experienced team specializing in accounting and finance, capital raising and administrative operations via Brio Financial Group, a US-based financial and management consulting firm, of which Mr. Babbar is a Director. This partnership will also be instrumental as the Company advances preparations for its NASDAQ uplisting.

[Explore the experience behind our expanding leadership team.](#)

Traction

- L-DOS47 Monotherapy Publication: *Frontiers in Oncology* has published [results from our earlier Phase I/II study of L-DOS47 in NSCLC](#), findings that continue to inform and propel our new combination trial with pembrolizumab.
- Interview with our CEO, Thomas Mehring MD, PhD on the YouTube channel [Passive Income Investor](#) on how L-DOS47 contributes to transforming cold tumors into hot, immune-responsive ones.

Request a Meeting

We're building value—and momentum. If you're an investor aligned with our vision, we'd love to connect.

[Request a Meeting](#)

If you wish to unsubscribe from our newsletter, click [here](#)